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Purpose: To evaluate the effect of intravitreal bevacizumab on visual function and retinal thickness in patients with 
diabetic macular edema (DME).
Methods: Thirty eyes of twenty-eight patients (mean age, 57.9±13.8 years) with DME were included in this study. 
Complete ophthalmic examination, including determination of best-corrected visual acuity (BCVA), stereoscopic 
biomicroscopy, and retinal thickness measurement by optical coherence tomography (OCT), was done at 
baseline and at each follow-up visit. All patients were treated with a 0.05 mL intravitreal injection containing 
1.25 mg of bevacizumab.
Results: All patients completed 3 months of follow-up with a mean follow-up period of 5.26±2.39 months. The 
mean BCVA at baseline was 0.73±0.36 logMAR, which significantly improved to 0.63±0.41 (p=0.02), 0.58±0.36 
(p=0.003), and 0.61±0.40 logMAR (p=0.006) at 1 week, 1 month, and 3 months. Final BCVA analysis de-
monstrated that 15 eyes (50%) remained stable and 12 (40%) improved ≥2 lines on BCVA. The mean central 
retinal thickness was 498.96±123.99 µm at baseline and decreased to 359.06±105.97 (p<0.001), 334.40±121.76 
(p<0.001), 421.40±192.76 µm (p=0.035) at 1 week, 1 month, and 3 months. No ocular toxicity or adverse effects 
were observed.
Conclusions: Intravitreal bevacizumab injection resulted in significant improvement in BCVA and central retinal 
thickness as early as 1 week after injection in patients with DME, and this beneficial effect persisted for up to 3 
months. However, the slight reduction in this improvement at 3 months suggests that repeated bevacizumab 
injections might be necessary. To evaluate the long-term safety and efficacy, further prospective randomized 
controlled clinical trials will be needed.
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Diabetic macular edema (DME) is the leading cause of visual 
loss in patients with diabetes mellitus, and it frequently leads 
to irreversible changes in visual acuity.
1 DME is caused by 
excessive vascular permeability, which leads to leakage of 
fluid and plasma constituents, such as lipoproteins, into the 
retina. This then causes retinal thickening. The Early Treatment 
Diabetic Retinopathy Study (ETDRS) showed that focal laser 
photocoagulation is beneficial in the treatment of clinically 
significant macular edema, reducing the rate of moderate 
visual loss by 50%.
2 However, only 3% of patients improved 
by ≥3 lines of vision by the end of the study. Intravitreal 
triamcinolone acetonide (IVTA) injection has proven effective 
in improving vision and reducing macular thickness in DME, 
both as an initial treatment and as a second line therapy after 
unsuccessful laser therapy.
3,4 However, its effect is temporary, 
and a number of side effects have been reported.
5,6 Conse-
quently, its therapeutic value remains unclear.
Vascular endothelial growth factor (VEGF) has been imp-
licated as an important factor in the breakdown of the blood- 
retina barrier, with increased vascular permeability resulting 
in retinal edema in diabetic patients through affecting endo-
thelial tight junction proteins.
7 While the normal human 
retina contains VEGF, hypoxia stimulates the secretion of 
VEGF from retinal pigment epithelial cells.
8,9 VEGF levels 
are significantly elevated in eyes with DME.
10,11 In addition, 
VEGF concentrations are significantly higher in eyes with 
extensive macular leakage when compared to eyes with 
minimal leakage.
11 Therefore anti-VEGF treatments have been 
proposed as an alternative adjunctive treatment for DME.
12 
Bevacizumab (Avastin, Genentech Inc., San Francisco, CA) 
is a complete full-length humanized antibody that binds to all 
subtypes of VEGF; it has been used successfully as a systemic 
drug in tumor therapy.
13 Recent studies have demonstrated 
the usefulness of intravitreal injections of bevacizumab in the 
reduction of macular edema secondary to central retinal vein Korean J Ophthalmol Vol.23, No.1, 2009
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Diabetes type 1:2 5:25
         duration (years) 15.9±7.6
Hypertension 10
Stage of retinopathy, severe NPDR* : PDR
† 12:18
Preoperative treatment, focal laser treatment 8
 panretinal  photocoagulation 15
intravitreal injection of triamcinolone 4
pars plana vitrectomy 6
Mean follow-up period (months) 5.26±2.39
Baseline visual acuity (logMAR) 0.73±0.36
Baseline central retinal thickness (µm) 498.96±123.99
* NPDR=noproliferative diabetic retinopathy; 
† PDR=proliferative diabetic retinopathy.
occlusion, vascular permeability, fibrovascular proliferation 
in retinal neovascularization secondary to proliferative diabetic 
retinopathy (PDR), and choroidal neovascularization secondary 
to age-related macular degeneration (AMD).
14-17
The purpose of  this retrospective study was to evaluate the 
effect of intravitreal bevacizumab on visual function and 
retinal thickness in patients with DME.
Materials and Methods
The present study was designed as a retrospective, con-
secutive case series study of eyes with DME treated with 
off-label intravitreal bevacizumab between March 2007 and 
February 2008. We reviewed the clinical records of 28 con-
secutive patients (30 eyes) with DME treated with at least 
one intravitreal injection of 1.25 mg of bevacizumab. Because 
there are no evidence-based indications for the treatment of 
DME with bevacizumab, we included a wide range of patients 
with diffuse, clinically significant DME who did not respond 
to other treatments such as photocoagulation, intravitreal 
triamcinolone injection, or pars plana vitrectomy. The inclusion 
criteria for the study eye included (1) best-corrected visual 
acuity (BCVA) ≤20/40, (2) clinically definite retinal thickening 
due to DME involving the center of the macula, (3) optical 
coherence tomography (OCT) central retinal thickness ≥275 
µm, and (4) no history of treatment for DME within the prior 
3 months. Exclusion criteria included macular edema due to 
a cause other than diabetes, other ocular condition that might 
affect macular edema or alter visual acuity, and evidence of 
external ocular infection.
Each patient underwent a complete eye examination, 
including determination of BCVA, slit-lamp examination, 
intraocular pressure (IOP) measurement, stereoscopic bio-
microscopy of the retina using a 90-diopter lens, and retinal 
thickness measurement by OCT (Stratus OCT model 3000; 
Carl Zeiss Meditec Inc., San Leandro, CA), at baseline and at 
each visit. Patients were examined at 1 week and 1 month 
after injection, and then at 1- or 2-month intervals at the 
discretion of the investigator. OCT images were obtained by 
fast macular thickness map scan (6-radial line pattern), and 
the central retinal thickness was measured using retinal map 
analysis for the calculation of average thickness at the center 
point. Each patient’s BCVA was transferred from his or her 
records and converted to a logarithm of the minimum angle 
of resolution (logMAR) scale for analysis.
Topical anesthesia was induced by applying proparacaine 
(0.5%) eye drops before injection. The conjunctiva bulbi and 
the fornices were repeatedly rinsed with povidone-iodine, 
which was also applied to the eyelid margins and the lashes 
to avoid expression of the meibomian glands. After appli-
cation of a sterile drape and subconjunctival injection of 
anesthesia (2% lidocaine containing 1:100,000 epinephrine), 
a 30-gauge needle on a 1 cm
3 syringe was used to inject 
bevacizumab intravitreally through the pars plana 3.5 to 4.0 mm 
posterior to the limbus, at a dose of 1.25 mg in 0.05 mL. The 
needle was carefully removed using a sterile cotton applicator 
to prevent reflux. After injection, antibiotic eye drops were 
applied four times per day for 3 days.
All patients provided written informed consent, and they 
were informed of the off-label use of the drug and its potential 
risks and benefits, as well as the likelihood that additional 
treatments might be required. The paired t-test was used for 
comparison of preoperative and postoperative BCVA and 
central retinal thickness. The multiple regression analysis 
was performed to evaluate the associated factors influencing 
treatment success, and Mann-Whitney U test was used to 
compare response to treatment between nonvitrectomized 
eyes and previously vitrectomized eyes. For all statistical 
tests, a p value <0.05 was considered statistically significant. 
The data were analyzed using statistical software (SPSS, 
version 12.0, SPSS Inc, Chicago, Illinois, USA).
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Fig. 1. Changes in best-corrected visual acuity (BCVA) and central 
retinal thickness measured by optical coherence tomography (OCT) 
after intravitreal bevacizumab injection.
Table 2. Best-corrected visual acuity (BCVA) analysis
First Week First Month Third Month
No. of Eyes Percentage No. of Eyes Percentage No. of Eyes Percentage
Decreased ≥2 lines of BCVA 2 7% 1 3% 3 10%
Remained stable 17 57% 16 53% 15 50%
Improved ≥2 lines of BCVA 11 37% 13 43% 12 40%
A                                                                                           B
Fig. 2. Development of visual acuity (logMAR) evaluated after 1 month (A) and 3 months (B) of follow-up.
Thirty eyes (28 patients) with a minimum of 3 months 
follow-up were included for analysis. The mean patient age 
was 57.9±13.8 years, and 60% were male (18 men, 12 women). 
All patients completed 3 months of follow-up, with a mean 
follow-up period of 5.26±2.39 months (range, 3-11 months). 
Type 2 diabetes was present in 83.3% of patients, and type 1 
diabetes was present in 16.7% of patients. Eighteen eyes 
(60%) exhibited PDR, and twelve exhibited severe nonpro-
liferative diabetic retinopathy (NPDR). Twenty-five eyes 
(83.3%) had received at least one alternative therapy before 
intravitreal bevacizumab injection. Focal laser therapy had 
been applied once in 4 eyes and more than twice in 4 eyes. 
Full scatter panretinal laser therapy had been performed on 
15 eyes (50%), and 6 eyes (20%) had undergone pars plana 
vitrectomy. Previous intravitreal injection of triamcinolone 
acetonide had been performed on 4 eyes at least 3 months 
before undergoing intravitreal bevacizumab injection. Addi-
tional baseline characteristics by treatment group are depicted 
in Table 1.
Improvements in visual acuity were noted from 1 week 
after intravitreal bevacizumab injection, and these statistically 
significant changes continued throughout the 3-month follow- 
up visit (Fig. 1). At baseline, the mean BCVA was 0.73±0.36 
logMAR. This improved significantly to 0.63±0.41 (p=0.02), 
0.58±0.36 (p=0.003), and 0.61±0.40 logMAR (p=0.006) at 
1 week, 1 month, and 3 months, respectively. At 3-month 
follow-up, the BCVA was slightly decreased, but there was 
no significant difference in the mean BCVA between the 1- 
and 3-month follow-up visits (p=0.536). The visual acuity 
results are summarized in Figure 2. Final BCVA analysis by 
subgroup demonstrated that 15 (50%) of 30 eyes remained 
stable, 12 (40%) improved ≥2 lines on BCVA, and 3 (10%) 
deteriorated ≥2 lines on BCVA (Table 2).
Mean central retinal thickness was 498.96±123.99 µm 
(range, 275-733 µm) at baseline by OCT. At 1 week post-
operatively, the mean central retinal thickness measurement 
decreased to 359.06±105.97 µm (p<0.001), and this signi-
ficant improvement of retinal thickening continued through 
the 1- and 3-month follow-up visits (p<0.001 and p=0.035, Korean J Ophthalmol Vol.23, No.1, 2009
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A                                                                                       B
Fig. 3. Development of central retinal thickness measured by optical coherence tomography after 1 month (A) and 3 months (B) of follow-up.
respectively) (Fig. 1). However, at 3-month follow-up, mean 
central retinal thickness significantly increased to 421.40± 
192.76 µm, compared with 1-month follow-up (334.40± 
121.76 µm, p=0.044). Figure 3 summarizes OCT-measured 
retinal thickness results.
Changes in visual acuity and changes in central retinal 
thickness did not vary substantially according to subject age 
(p=0.54 and p=0.95, respectively), diabetic retinopathy severity 
(p=0.88 and p=0.14), previous focal laser treatment (p=0.09 
and p=0.76), previous panretinal photocoagulation (p=0.31 
and p=0.93), or previous IVTA injection (p=0.79 and p=0.83). 
There was a suggestion of greater effect on visual acuity in 
eyes that had not undergone pars plana vitrectomy compared 
with previously vitrectomized eyes (p=0.025). The same 
effect was not observed concerning central retinal thickness 
(p=0.98). Eyes with thicker retinas at baseline experienced a 
greater absolute and relative reduction in central retinal 
thickness at 1 month (p=0.001 and p=0.031, respectively), but 
changes in visual acuity did not differ according to baseline 
visual acuity or baseline central retinal thickness (p=0.06 and 
p=0.63, respectively).
There were no cases of endophthalmitis, uveitis, IOP 
increase, or severe decrease in vision immediately after 
injection. At 3 months, no ocular or systemic adverse events 
were reported, including thromboembolic events (cerebro-
vascular accidents, transient ischemic attacks, myocardial 
infarctions, or peripheral vascular disease).
Discussion
DME is a manifestation of diabetic retinopathy that produces 
severe visual impairment. Although several treatment mo-
dalities are under investigation, the only demonstrated means 
to reduce the risk of vision loss from DME are laser photo-
coagulation, as demonstrated by the ETDRS
2; intensive 
glycemic control, as demonstrated by the Diabetes Control 
and Complications Trial and the United Kingdom Pro-
spective Diabetes Study; and blood pressure control, as 
demonstrated by the United Kingdom Prospective Diabetes 
Study.
18,19 However, there has been interest in other treatment 
modalities, such as pharmacologic therapy with oral protein 
kinase C inhibitors and the use of intravitreal corticosteroids, 
because most laser-treated DME eyes do not exhibit satis-
factory improvements in VA.
20,21 Antibodies targeted to 
VEGF have also generated considerable interest and are 
being investigated.
VEGF is an endothelial cell-specific mitogen and angio-
genic inducer in a variety of in vitro and in vivo models.
22 It is 
upregulated by hypoxia, and it plays a role in DME and 
contributes to the excessive vascular permeability that leads 
to macular edema in diabetic patients. Bevacizumab is a 
full-length humanized monoclonal antibody that binds and 
inhibits all biologically active isoforms of VEGF. Although 
preclinical experimental data from primates suggested that 
the full-length antibody might not penetrate the internal 
limiting membrane of the retina, recent studies have shown 
full-thickness penetration of the retina within 24 hours.
23,24 
To our knowledge, all clinical and experimental studies 
presented thus far have not noted drug-related toxic effects 
in any retinal structure.
14-17,25-30  Intravitreal injection of 
bevacizumab appears to have good efficacy in the treatment 
of wet AMD as a new treatment option. Injection of bevaci-
zumab into the vitreous cavity, as is presently done mostly 
for patients with AMD, is based on the results of clinical 
reports clearly indicating an increase in visual acuity and a 
decrease in retinal thickness.
15,16,27 In addition, other VEGF 
inhibitors, such as pegaptanib sodium (Macugen)－which 
binds to one VEGF isoform－have also been successfully 
used to treat DME in a published randomized, controlled, 
double-masked phase II multicenter trial. Subjects treated JW Seo and IW Park. INTRAVITREAL BEVACIZUMAB FOR TREATMENT OF DME
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with pegaptanib had better visual acuity outcomes, were 
more likely to have reduction in central retinal thickness, and 
were less likely to need additional photocoagulation therapy 
at follow-up.
12 In light of this information, intravitreal beva-
cizumab injection is expected to have good efficacy in the 
treatment of DME.
Recently, Haritoglou et al.
28  published a prospective, 
noncomparative case series of patients with DME treated 
with 1.25 mg bevacizumab. There was a significant reduction 
in macular thickness at 2 weeks (p=0.002) and although mean 
visual acuity improved significantly at 6 weeks (p=0.02), this 
was not sustained at 12 weeks. In the present investigation, 
however, we found that significant improvement in both visual 
acuity and retinal thickness was achieved soon after intra-
vitreal bevacizumab injection, and the beneficial effects 
lasted for 3 months. The mean BCVA improved from 
0.73±0.36 logMAR at baseline to 0.63±0.41 logMAR at 1- 
week follow-up (p=0.02), and the mean central retinal 
thickness as measured by OCT also decreased significantly 
from 498.96±123.99 µm at baseline to 359.06±105.97 µm at 
1-week follow-up (p<0.001). At 1 month after the injection 
of bevacizumab, this beneficial effect on BCVA and central 
retinal thickness appeared to be most prominent in the 
current study. Thirteen (43%) of 30 eyes showed an improve-
ment in BCVA by 2 or more lines, and only 1 eye (3%) 
decreased  ≥2 lines on BCVA at 1-month follow-up. In 
addition, the central retinal thickness showed a considerable 
reduction (33%): from 498.96±123.99 µm at baseline to 
334.40±121.76 µm at 1 month. Although the duration of 
action of intravitreal bevacizumab is unknown, recent electro-
physiologic and retinal penetration studies have reported that 
full thickness retinal penetration is present at 24 hours.
24 This 
may explain the earlier clinical effects of intravitreal bevaci-
zumab observed in the current study.
A recent report from the Pan-American Collaborative 
Retina Study Group showed a significant decrease of DME 
one month after intravitreal injection of bevacizumab, and 
those decreased levels were kept for up to six months.
29 In 
our study, the reduction of central retinal thickness and the 
improvement of BCVA were observed at 1 week, and these 
results were maintained for up to 3 months. However, at 
3-month follow-up, a slight decrease in visual acuity and an 
increase in retinal thickness were observed as compared with 
the 1-month follow-up. The central retinal thickness increased 
significantly from 334.40±121.76 µm at 1 month to 421.40± 
192.76 µm at 3 months (p=0.044). This slight reduction in 
the improvement of visual acuity and central retinal thickness 
at 3-month follow-up suggests that repeated intravitreal beva-
cizumab injections may be necessary within 3 months to 
maintain a beneficial effect. In this study, 6 (20%) of 30 eyes 
received the second injection at a mean of 3.8 months. 
Re-treatment was done only in cases of BCVA deterioration 
and increased macular edema on OCT. It is possible that a 
different dosing schedule, such as a series of injections every 
3 months for an extended period, may be superior to the 
method used in this study. However, we chose to re-treat the 
recurrent cases only, because data concerning toxicity and 
duration of action of intravitreal bevacizumab were not 
sufficient at the beginning of the study.
The breakdown of endothelial tight junctions and loss of 
the blood-retina barrier that lead to DME can be associated 
with both nonproliferative diabetic retinopathy and PDR. 
The present study demonstrates a comparable population of 
PDR and NPDR patients with macular edema. The results of 
the present study indicate that intravitreal bevacizumab in-
jections may have a beneficial effect on retinal thickness and 
visual acuity, independent of the type of diabetic retinopathy. 
In addition, previous treatments, such as focal laser treatment, 
panretinal photocoagulation, or IVTA injection, did not 
influence the results of the study, except in the case of 
previous vitrectomy. Previously vitrectomized eyes showed 
no increase in visual acuity, and this finding is consistent 
with a previous study that found there was no change in 
BCVA or foveal thickness after intravitreal bevacizumab 
injection for DME in previously vitrectomized eyes.
30 This 
outcome may be attributable to rapid clearance of intravitreal 
bevacizumab and insufficient sustained therapeutic levels in 
vitrectomized eyes. Further studies are warranted due to the 
relatively small number of participants in this study.
In conclusion, intravitreal bevacizumab injection appears 
to result in significant improvement in BCVA and reduction 
in central retinal thickness as early as 1 week after injection, 
and this beneficial effect was shown to persist for up to 3 
months. However, the slight reduction in improvement in 
visual acuity and central retinal thickness at 3-month follow- 
up suggests that repeated bevacizumab injections might be 
necessary within 3 months to maintain its effect, as the drug 
is well tolerated and there are no safety concerns. To evaluate 
the long-term safety and efficacy of this new treatment, 
further prospective randomized controlled clinical trials will 
be needed, with scheduled re-injection and longer follow-up.
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